We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance Pipeline Strong, Dependence on Yupelri a Concern
Read MoreHide Full Article
Theravance Biopharma, Inc. (TBPH - Free Report) is a biopharmaceutical company focused on developing treatments targeting various therapeutic areas such as infectious, respiratory, gastrointestinal, cardiovascular, renal, inflammation and immunology diseases.
The company received a huge boost when the FDA approved Yupelri, a long-acting muscarinic antagonist (LAMA), as a once-daily, nebulized treatment of chronic obstructive pulmonary disease (COPD) last November.
Theravance has a collaboration deal with Mylan for the development and commercialization of Yupelri. Both companies formally launched Yupelri in early 2019 and the product is witnessing a strong uptake ever since.
Mylan and Theravance are sharing US profits and losses reported in connection with the commercialization of Yupelri. While Mylan gets 65% of the profits, Theravance is entitled to receive 35%. The product has witnessed strong customer acceptance and brand performance across the key market metrics.
Notably, in November 2018, Theravance completed the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.
Meanwhile, Theravance has an economic interest in GlaxoSmithKline's (GSK - Free Report) COPD drug Trelegy Ellipta and earns royalties on its sales.
This apart, Theravance has a promising pipeline portfolio, which is progressing well. Last month, the company announced promising outcomes from a phase I study on its inhaled, lung-selective pan-Janus kinase (JAK) inhibitor TD-8236. The candidate is being developed for the treatment of inflammatory lung diseases with minimal systemic exposure.
Theravance also has a collaboration agreement with Johnson & Johnson's (JNJ - Free Report) subsidiary Janssen to develop its JAK inhibitor TD-1473 for treating inflammatory intestinal diseases. A phase II study on TD-1473 to treat Crohn's disease and a phase IIb/III study for ulcerative colitis are ongoing. The company plans to report data from both these studies on TD-1473 by late 2020.
Theravance is also evaluating TD-9855 in a phase III study for treating patients with symptomatic neurogenic orthostatic hypotension (nOH).
Successful development and subsequent approval of these candidates will be a huge boost to the company given their potential to offer transformational value to patients and healthcare providers.
However, with the potential sale of Vibativ, Theravance is now solely dependent on profit-sharing revenues from Mylan for Yupelri and collaboration revenues from J&J for funding its pipeline development. Any agreement termination regarding these in the future might be a massive setback for the company.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Theravance Pipeline Strong, Dependence on Yupelri a Concern
Theravance Biopharma, Inc. (TBPH - Free Report) is a biopharmaceutical company focused on developing treatments targeting various therapeutic areas such as infectious, respiratory, gastrointestinal, cardiovascular, renal, inflammation and immunology diseases.
The company received a huge boost when the FDA approved Yupelri, a long-acting muscarinic antagonist (LAMA), as a once-daily, nebulized treatment of chronic obstructive pulmonary disease (COPD) last November.
Theravance has a collaboration deal with Mylan for the development and commercialization of Yupelri. Both companies formally launched Yupelri in early 2019 and the product is witnessing a strong uptake ever since.
Mylan and Theravance are sharing US profits and losses reported in connection with the commercialization of Yupelri. While Mylan gets 65% of the profits, Theravance is entitled to receive 35%. The product has witnessed strong customer acceptance and brand performance across the key market metrics.
Notably, in November 2018, Theravance completed the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.
Meanwhile, Theravance has an economic interest in GlaxoSmithKline's (GSK - Free Report) COPD drug Trelegy Ellipta and earns royalties on its sales.
This apart, Theravance has a promising pipeline portfolio, which is progressing well. Last month, the company announced promising outcomes from a phase I study on its inhaled, lung-selective pan-Janus kinase (JAK) inhibitor TD-8236. The candidate is being developed for the treatment of inflammatory lung diseases with minimal systemic exposure.
Theravance also has a collaboration agreement with Johnson & Johnson's (JNJ - Free Report) subsidiary Janssen to develop its JAK inhibitor TD-1473 for treating inflammatory intestinal diseases. A phase II study on TD-1473 to treat Crohn's disease and a phase IIb/III study for ulcerative colitis are ongoing. The company plans to report data from both these studies on TD-1473 by late 2020.
Theravance is also evaluating TD-9855 in a phase III study for treating patients with symptomatic neurogenic orthostatic hypotension (nOH).
Successful development and subsequent approval of these candidates will be a huge boost to the company given their potential to offer transformational value to patients and healthcare providers.
However, with the potential sale of Vibativ, Theravance is now solely dependent on profit-sharing revenues from Mylan for Yupelri and collaboration revenues from J&J for funding its pipeline development. Any agreement termination regarding these in the future might be a massive setback for the company.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>